格隆汇9月23日丨昭衍新药(06127.HK)公告，有关公司与专业投资机构合作参与投资设立产业基金事 项。近日，公司收到招商局资本管理(北京)有限公司的通知，本基金已在中国证券投资基金业协会完成 私募投资基金备案登记手续，并取得《私募投资基金备案证明》，备案信息如下： 3．托管人名称：招商银行股份有限公司 4．备案编码：SBGB42 5．备案日期：2025年9月21日 1．基金名称：服务贸易创新发展引导基金二期(有限合伙) 2．管理人名称：招商局资本管理(北京)有限公司 ...

Group 1 - The cell immunotherapy sector experienced a decline of 2.75%, ranking among the top losers in the concept sector, with ST Zhongzhu hitting the daily limit down [1] - Major stocks within the cell immunotherapy sector that saw significant declines include Zhaoyan New Drug, Jimin Health, and Boteng Co., with respective drops of 6.04%, 5.45%, and 5.34% [1][2] - The sector faced a net outflow of 1.61 billion yuan from main funds, with 48 stocks experiencing outflows, and six stocks seeing outflows exceeding 100 million yuan, led by Hengrui Medicine with a net outflow of 293 million yuan [2] Group 2 - The top gainers in today's concept sectors included the SMIC concept with a rise of 1.22% and the National Big Fund holding with an increase of 1.08% [2] - The main inflows were observed in stocks such as Betta Pharmaceuticals, Chutian Technology, and Rongchang Bio, with net inflows of 35.97 million yuan, 21.30 million yuan, and 14.08 million yuan respectively [4] - The overall market sentiment reflected a mixed performance across various sectors, with notable declines in the Huawei Pangu and MLOps concepts, down 3.69% and 3.31% respectively [2]

海外監管公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年9月23日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫雲霞女士、羅樨女士及顧靜良先生，及獨立非執行董事張帆先生、楊福全 ...

Core Viewpoint - The company, Zhaoyan New Drug (603127), has made a significant investment in financial products, which is expected to enhance its capital returns without affecting its financial stability or operational liquidity [1]. Group 1: Stock Performance - As of September 19, 2025, Zhaoyan New Drug's stock closed at 38.38 CNY, down 4.43% from the previous trading day [1]. - The stock opened at 39.5 CNY, reached a high of 40.55 CNY, and a low of 38.3 CNY, with a trading volume of 1.336 billion CNY and a turnover rate of 5.42% [1]. Group 2: Investment Announcement - The company announced that its subsidiary, Zhaoyan (Suzhou) New Drug, subscribed to two financial products from Industrial and Commercial Bank of China, totaling 40 million CNY [1]. - Including previously unredeemed products, the total investment amounts to 410 million CNY [1]. - The financial products are non-principal guaranteed, floating yield type, with no fixed term and flexible redemption arrangements [1]. Group 3: Regulatory Compliance - The investment constitutes a disclosure transaction as the combined applicable percentage rate is above 5% but below 25%, requiring compliance with notification and announcement regulations, but exempt from shareholder approval [1]. - The board believes that subscribing to these products will enhance capital returns and is in the overall interest of the company and its shareholders [1].

香港联交所最新资料显示，9月16日，富达国际减持昭衍新药（603127）(06127)161.08万股，每股均价 21.5742港元，总金额约为3475.17万港元。减持后最新持股数目为1145.48万股，最新持股比例为 9.63%。 本交易涉及其他关联方：Pandanus Associates Inc.、Pandanus Partners L.P.。 ...

本交易涉及其他关联方：Pandanus Associates Inc.、Pandanus Partners L.P.。 智通财经APP获悉，香港联交所最新资料显示，9月16日，富达国际减持昭衍新药(06127)161.08万股， 每股均价21.5742港元，总金额约为3475.17万港元。减持后最新持股数目为1145.48万股，最新持股比例 为9.63%。 ...

Core Viewpoint - Zhaoyan New Drug (06127.HK) announced an investment in two Industrial and Commercial Bank of China wealth management products totaling RMB 40 million, bringing the total investment in such products to RMB 410 million as of the announcement date [1] Group 1 - The company has subscribed to two wealth management products from the Industrial and Commercial Bank of China [1] - The total investment amount in these wealth management products is RMB 410 million, which includes the newly subscribed amount and the amount that has not yet been redeemed [1]

Group 1 - The company, Zhaoyan New Drug (603127), announced an agreement with Industrial and Commercial Bank of China to subscribe to two wealth management products totaling RMB 40 million [1] - The total investment amount in these wealth management products, including those not yet redeemed as of the announcement date, is RMB 410 million [1]

Core Viewpoint - Zhaoyan New Drug (06127.HK) announced an investment in two Industrial and Commercial Bank of China wealth management products totaling RMB 40 million, bringing the total investment in such products to RMB 410 million as of the announcement date [1] Group 1 - The company has subscribed to two wealth management products from the Industrial and Commercial Bank of China [1] - The total investment amount in these wealth management products is RMB 410 million, which includes the newly subscribed amount and the amount that has not yet been redeemed [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 董 事 會 謹 此 公 佈，於2025年9月19日（交 易 時 間 後），本 集 團 成 員 公 司 昭 衍（蘇 州） 新 藥 剛 與 工 商 銀 行 訂 立 協 議，認 購 兩 項 工 商 銀 行 理 財 產 品 合 共 人 民 幣40,000,000 元，且 連 同 本 公 告 日 期 仍 未 贖 回 的 該 等 工 商 銀 行 理 財 產 品 合 計 投 資 總 額 為 人 民 幣410,000,000元。 （股 份 代 號：6127） 須予披露交易 認購金融產品 認購金融產品 董 事 會 謹 此 公 佈，於2025年9月19日（交 易 時 間 後），本 集 ...